ST. LOUIS (CN) — Express Scripts filed a federal lawsuit against the Federal Trade Commission on Tuesday, claiming its report blaming the pharmacy benefit management industry for rising drug costs was ...

Express Scripts Holding, a pharmacy benefit manager that negotiates drug prices for many health plans, will launch a formulary with lower list price drugs in an effort to reduce reliance on rebates ...

If you've been relying on Express Scripts for your 90-day refills and home delivery, 2026 brings a critical shift: a new 'Copay Assurance' program that caps out-of-pocket costs, paired with stricter ...

The FTC sued Cigna-owned Express Scripts, CVS-owned Caremark and UnitedHealth-owned Optum Rx in September, arguing that the drug middlemen prefer more expensive insulin products because they result in ...

If you've spent years managing your health across MyChart, Express Scripts, and WellCare, you know the frustration of disjointed alerts and opaque prior authorization processes. But as of May 2026, ...

The agreement announced Thursday follows a series of disputes between Walgreen and Express Scripts that ended with the discontinuation of the contract between the drugstore operator and the pharmacy ...

Another major pharmacy benefit manager is adding Humira biosimilars to its formulary beginning next year. Express Scripts, which is part of Cigna's Evernorth subsidiary, said Monday that it will add ...

The company that manages Tricare's pharmacy benefits will give thousands of independent and community pharmacies that left the network last month an opportunity to rejoin -- but it's unclear whether ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Express Scripts, the pharmacy benefits services business of The Cigna Group's Evernorth, has entered into a collaboration with CPESN USA, a network of pharmacy providers that delivers health services, ...

The company initiated its next development program for etripamil, starting a Phase III AFib-RVR trial. “We have initiated our Phase III trial for atrial fibrillation with rapid ventricular rate or ...